2m 2m 2m 2m 2m 2m 2m
CITIUS PHARMACTC (CTXR)
NASDAQ
$0.59-$0.02 (-2.70%)
Price as of Jun 03, 2026 7:10 PM EDT- $18.0MMarket Cap
- -30.25%1-Year Change
- BiotechnologyIndustry
CITIUS PHARMACTC (CTXR)
$0.59-$0.02 (-2.70%)
Annual
Quarterly
09/30/2025 | 09/30/2024 | 09/30/2023 | 09/30/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | 90,000 0.00% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 -100.00% | 90,000 0.00% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -9.2M -23.10% | -11.9M -19.66% | -14.8M -16.06% | -17.7M +44.24% | |
Depreciation and Amortization Expense | N/A N/A | 1,432 -46.33% | 2,668 -8.72% | 2,923 +95.91% | |
Total Operating Expenses | 38.5M -8.26% | 42.0M +14.33% | 36.7M +10.25% | 33.3M +41.58% | |
Operating Profit | -38.5M -8.26% | -42.0M +14.33% | -36.7M +10.25% | -33.3M +41.58% | |
Interest Income | 110,081 -85.48% | 758,000 -35.73% | 1.2M +369.14% | 251,399 -3.98% | |
Interest Expense | -218,032 N/A | N/A N/A | N/A N/A | -1,233 -88.62% | |
Interest Income and Expense and Net | -107,951 -114.24% | 758,000 -35.73% | 1.2M +371.45% | 250,166 -0.33% | |
Total Nonoperating Income and Expense | -157,701 -105.01% | 3.1M -33.98% | 4.8M N/A | N/A N/A | |
Income before Taxes | -38.7M -0.43% | -38.8M +21.53% | -32.0M -3.32% | -33.1M +34.93% | |
Income Taxes | 1.1M +83.50% | 576,000 0.00% | 576,000 0.00% | 576,000 +46,615.33% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -39.7M +0.80% | -39.4M +21.15% | -32.5M -3.26% | -33.6M +45.92% | |
Net Income from Continuing Operations Applicable to Common | -37.4M -6.85% | -40.2M +19.27% | -33.7M +0.16% | -33.6M +37.28% | |
Basic EPS and Net Income | -3.38 -43.38% | -5.97 N/A | N/A N/A | -0.23 0.00% | |
Diluted EPS and Net Income | -3.38 -43.38% | -5.97 N/A | N/A N/A | -0.23 0.00% | |
Basic Weighted Average Shares | 11.1M +64.49% | 6.7M -95.55% | 151.3M +3.57% | 146.1M +34.52% | |
Diluted Weighted Average Shares | 11.1M +64.49% | 6.7M -95.55% | 151.3M +3.57% | 146.1M +34.52% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 4.3M +30.76% | 3.3M -87.72% | 26.5M -36.51% | 41.7M -40.47% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 4.3M +30.76% | 3.3M -87.72% | 26.5M -36.51% | 41.7M -40.47% | |
Total Current Assets | 27.9M +96.44% | 14.2M -58.63% | 34.4M -22.87% | 44.6M -38.80% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | 1,432 -65.07% | 4,100 -41.62% | |
Total Long-Term Assets | 102.2M 0.00% | 102.2M +48.56% | 68.8M 0.00% | 68.8M 0.00% | |
Total Assets | 130.9M +12.25% | 116.7M +12.59% | 103.6M -9.11% | 114.0M -19.96% | |
Income Taxes Payable | 7.8M +15.74% | 6.7M +9.38% | 6.1M +10.36% | 5.6M +11.55% | |
Total Short-Term Debt | 1.0M -99.67% | 300.0M N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 44.9M +25.41% | 35.8M +519.74% | 5.8M +27.57% | 4.5M +13.75% | |
Total Long-Term Debt | 1.0M N/A | N/A N/A | N/A N/A | 172,970 0.00% | |
Total Long-Term Liabilities | 16.3M +20.95% | 13.4M +7.26% | 12.5M +8.05% | 11.6M +8.97% | |
Total Liabilities | 53.4M +25.52% | 42.5M +249.35% | 12.2M +15.20% | 10.6M +9.61% | |
Retained Earnings | -238.8M +18.59% | -201.4M +24.13% | -162.2M +25.09% | -129.7M +35.02% | |
Total Stockholders Equity | 67.6M -3.61% | 70.1M -22.85% | 90.8M -11.67% | 102.8M -22.21% | |
Total Shares Outstanding | 18.1M +149.31% | 7.2M -95.44% | 158.9M +8.65% | 146.2M +0.16% | |
Cash Flow | |||||
Cash from Operating Activities | -26.6M -5.85% | -28.2M -2.96% | -29.1M +2.46% | -28.4M +16.95% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -5.8M +15.00% | -5.0M N/A | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 33.3M +233.96% | 10.0M -27.89% | 13.8M N/A | N/A N/A | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | -37,017.83% +41.58% | |
Return on Assets | -32.10% -10.33% | -35.80% +19.69% | -29.91% +13.99% | -26.24% +5.96% | |
Return on Equity | -57.75% +17.85% | -49.00% +45.81% | -33.61% +17.39% | -28.63% +2.98% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | 0.00% N/A | |
Current Ratio | 0.62 +56.61% | 0.40 -93.32% | 5.95 -39.54% | 9.84 -46.20% | |
Cash Ratio | 0.09 +4.30% | 0.09 -98.02% | 4.58 -50.24% | 9.21 -47.67% | |
Debt-to-Equity Ratio | 0.03 N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.02 N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow